ALLMedicine™ Acquired Pure Red Cell Aplasia Center
Research & Reviews 22 results
https://clinicaltrials.gov/ct2/show/NCT04423367
Dec 6th, 2022 - This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579546
Journal of Medical Case Reports; Karrat I, Eddou H
Oct 19th, 2022 - Coronavirus disease 2019, caused by severe acute respiratory coronavirus 2, has been responsible, since December 2019, for a severe pandemic resulting in millions of deaths worldwide, and the number is still increasing. Although coronavirus diseas...
https://doi.org/10.1053/j.seminhematol.2022.07.001
Seminars in Hematology; Kawakami T, Nakazawa H et. al.
Sep 18th, 2022 - Acquired pure red cell aplasia (PRCA) is a syndrome characterized by anemia and a marked reduction of erythroid progenitor cells with various etiologies. The 3 major subtypes of PRCA are idiopathic PRCA, large granular lymphocytic leukemia-associa...
https://doi.org/10.12659/AJCR.935451
The American Journal of Case Reports; Kitpermkiat R, Thotsiri S et. al.
Jul 18th, 2022 - BACKGROUND Pure red cell aplasia (PRCA) is an uncommon cause of anemia in end-stage kidney disease (ESKD). It is attributed to recombinant human erythropoietin (rHuEPO) administration. Although immunosuppression is the mainstay therapy, its effect...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806328
Blood Advances; Nakazawa H, Sakai K et. al.
May 7th, 2022 - Acquired pure red cell aplasia (PRCA) is a rare syndrome characterized by anemia with reticulocytopenia and a marked reduction in erythroid precursors. Given its rarity, the true incidence is largely unknown, and epidemiological data representing ...
Clinicaltrials.gov 1 results
https://clinicaltrials.gov/ct2/show/NCT04423367
Dec 6th, 2022 - This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.
News 1 results
https://www.onclive.com/view/cracking-the-mgus-code-reveals-monoclonal-gammopathy-of-clinical-significance-
Nov 1st, 2022 - When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment. On initial patient consultation, gathering a detailed patient history and thorough physical exam can catch clinically signifi...